Professor, Medicine, Perelman School of Medicine

Hematology

Kenneth M. Algazy is an expert in the field of Hematology. He graduated from Temple University School of Medicine. He received awards:"America's Top Doctors", "America's Top Doctors for Cancer", "Philadelphia Magazine" and "Super Doctor". Dr. Kenneth M. Algazy has written publications. He has 28 publications published with PubMed. The lastest paper is: 'Thrombolysis of acute or subacute nonembolic arterial thrombosis.' Kenneth M. Algazy accepts Medicare.

Publications

---

• Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.
• Spontaneous smoking cessation before lung Cancer diagnosis.
• Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung Cancer.
• A population-based study of Lung carcinoma in Pennsylvania: comparison of Veterans Administration and civilian populations.
• Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell Lung carcinoma: long-term results and associations with patholog...
• Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced Cancer.
• Spinner's hematuria.
• Clinical and molecular features of small cell lung Cancer.
• Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with Cancer.
• A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors.
• Factors affecting the risk of Brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma.
• Pilot study of organ preservation multimodality therapy for locally advanced resectable oropharyngeal carcinoma.
• Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung Cancer.
• Warfarin-induced Skin necrosis in a patient with a mutation of the prothrombin gene.
• Endoscopic diagnosis of eosinophilic gastritis.
• A phase I study of WR-2721 in combination with total body irradiation (TBI) in patients with refractory lymphoid Malignancies.
• Fibrinolytic treatment of acute or subacute arterial Thrombosis.
• Thrombolysis of acute or subacute nonembolic arterial Thrombosis.
• Partial purification of thrombopoietin from the plasma of thrombocytopenic rabbits.
• Quantitative venographic assessment of Deep vein thrombosis in the evaluation of streptokinase and heparin therapy.
• A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine.
• Phase I trial of UFT/leucovorin and irinotecan in patients with advanced Cancer.
• Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced Cancer.
• A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck Cancer.
• Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
• Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid Malignancies.
• Gefitinib in patients with advanced non-small cell lung Cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania.

Schools

---

• Temple University School Of Medicine

• Abington Meml Hospital

• University Roch Strong Meml Hospital

• Johns Hopkins Med Center

Conditions Treated

---

• Anemia
• Antiphospholipid Syndrome (APS)
• Bladder Cancer
• Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
• View All

Doctors Specialties

---

• Hematology
• Medical Oncology
• Oncology

Accepted Insurances

---

Awards

---

• America's Top Doctors
• America's Top Doctors for Cancer
• Philadelphia Magazine
• Super Doctor

Education

---

• Johns Hopkins University
• University of Rochester
• Temple University School of Medicine

Hospital

---

• Hospital of the University of Pennsylvania
• Pennsylvania Hospital
• Philadelphia Veterans Affairs Medical Center
• Penn Presbyterian Medical Center

Drug Facts

---

NPI NUMBER		1124061403
NPPES Provider LastName		ALGAZY
NPPES Provider FirstName		KENNETH
NPPES Provider ZIPCode		191045127
NPPES Provider State		PA
Specialty Description		Hematology/Oncology
Total Claim Count		151.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1124061403
Last Name Of The Provider	ALGAZY
First Name Of The Provider	KENNETH
View All

Similar Doctors

---

	Dr. Ivan P. Maillard, MD This Doctor is OpenDoctor Recommended.
	Dr. Scot W. Ebbinghaus, MD This Doctor is OpenDoctor Recommended.
	Dr. Claire F. Friedman, MD
	Dr. Rene R. Rubin, MD This Doctor is OpenDoctor Recommended.
	Dr. Robert B. Sklaroff, MD This Doctor is OpenDoctor Recommended.
	Dr. Elizabeth P. Henske, MD
	Dr. Mitchell J. Goldstein, MD This Doctor is OpenDoctor Recommended.
	Dr. William J. Tester, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Robert F. Ozols, MD This Doctor is OpenDoctor Recommended.
	Dr. Kristine M. Ward, MD This Doctor is OpenDoctor Recommended.
	Dr. Michael Millenson, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Keerthi Gogineni, MD This Doctor is OpenDoctor Recommended.
	Dr. Jennifer M. Matro, MD This Doctor is OpenDoctor Recommended.
	Dr. Lawrence F. Brass, MD This Doctor is OpenDoctor Recommended.
	Dr. Chad J. Tarabolous, MD This Doctor is OpenDoctor Recommended.
	Dr. Robert L. Comis, MD This Doctor is OpenDoctor Recommended.
	Dr. Arati S. Desai, MD This Doctor is OpenDoctor Recommended.
	Dr. Edward A. Stadtmauer, MD This Doctor is OpenDoctor Recommended.
	Dr. Lewis J. Rose, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog